ArticleScience (New York, N.Y.)2025
Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- ATP-dependent chromatin remodelers in prostate cancer progression and therapeutic resistance.Endocrinology · 2026Review
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- FOXA1 drives chemoresistance through activating Wnt pathway in small cell lung cancer.Translational lung cancer research · 2026Article
- A ligandable PNT domain establishes ERG as a directly targetable oncogenic driver in prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.Communications biology · 2026Article
- Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocrine-related cancer · 2026Review
- Unstructured transcription factor interactions enable emergent specificity.Science (New York, N.Y.) · 2026Article
- 3D genome architecture and epigenetic regulation of lineage identity in advanced prostate cancer.Endocrinology · 2026Review
- IDH1 Mutations Are Associated with Favorable Outcomes in Prostate Cancer.European urology · 2026Article
- Rewiring Oncogenic Transcriptional Complexes with Domain-ALTeration Chimeras (DALTACs) in Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- STAG2 loss amplifies EWS-FLI1-driven microsatellite enhancer activity promoting Ewing sarcoma aggressiveness.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.Cancer research · 2026Article
- Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.EMBO molecular medicine · 2026Article
- FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.Cell reports · 2026Article
- Personalized genomic landscape of prostate cancer in African American men reveals novel drivers and therapeutic opportunities.PloS one · 2026Article
- Review
- Genomic Crosstalk Between Nuclear Receptors in Hormone-dependent Cancers.Endocrinology · 2025Review
- Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer.Oncogene · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Sanjana EyunniDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0006-5101-6506
Rahul MannanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6642-0468
Yuping ZhangDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Eleanor YoungDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-5393-530X
Qiuyang ZhangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0005-4954-9859
Jie LuoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Matthew PangMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Somnath MahapatraDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-9490-6353
Jean Ching-Yi TienDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-2684-4450
James M GeorgeMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-9723-6444
Mustapha JaberMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0003-1632-3154
Hamzah HakkaniMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0007-2147-8854
Sandra E CarsonMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-7716-9627
Abigail J ToddMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0009-0002-3379-2158
Noshad HosseiniMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-3761-0198
Mahnoor GondalMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.
Ryan J RebernickMichigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5532-581X
Xuhong CaoDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-2455-3086
Fengyun SuDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Rui WangDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-5356-9685
Rohit MehraDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6955-8884
Jing LiDepartment of Precision Medicine, Changhai Hospital, Second Military Medical University (Naval Medical University), Shanghai, China.
Marcin CieslikDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-9282-3415
Abhijit ParoliaDepartment of Pathology, University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0003-0238-221X
Funding
XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2MMICHIGAN MEDICAL SCIENTIST TRAINING PROGRAMT32GM007863 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COLLINS, KATHLEEN L. · 1985 to 2024
$38.3MTissue/InformaticsP50CA186786 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Robert Timothy Dess · 2014 to 2026
$27.6MExploring Precision Oncology: From Gene Fusions to lncRNAsR35CA231996 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHINNAIYAN, ARUL M · 2018 to 2024
$6.4MCellular and Molecular Biology at MichiganT32GM145470 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI John Chadwick Brenner · 2022 to 2026
$4.1MMichigan Medical Scientist Training Program 2025-2030T32GM156550 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Kathleen L. Collins · 2025 to 2026
$3.2MSWI/SNF chromatin remodelers in tumor-associated antigen-specific CD8+ cytotoxic T cellsK00CA245825 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PAROLIA, ABHIJIT · 2021 to 2024
$388kHoward Hughes Medical InstituteNCI NIH HHS K00 CA245825NCI NIH HHS P30 CA046592NCI NIH HHS P50 CA186786NCI NIH HHS R35 CA231996NIGMS NIH HHS T32 GM007863NIGMS NIH HHS T32 GM145470NIGMS NIH HHS T32 GM156550
Abstract
FOXA1 is altered in 10 to 40% of prostate cancers, yet its oncogenic mechanisms remain uncharacterized in vivo. We developed knock-in mouse models representing distinct classes of FOXA1 mutations. Histopathological and multiomic analyses of prostate tissues and organoids revealed that Class 1 mutations, in conjunction with
Indexed as
AdenocarcinomaCarcinogenesisCell PlasticityHepatocyte Nuclear Factor 3-alphaProstatic NeoplasmsAnimalsCell ProliferationGene Knock-In TechniquesHumansKruppel-Like Transcription FactorsMaleMechanistic Target of Rapamycin Complex 1MiceMice, TransgenicMutationReceptors, AndrogenFOXA1 protein, humanFoxa1 protein, mouseHepatocyte Nuclear Factor 3-alphaKruppel-Like Transcription FactorsMechanistic Target of Rapamycin Complex 1Receptors, AndrogenTrp53 protein, mouseTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.